T0	Participants 68 102	patients with Parkinson's disease.
T1	Participants 242 290	two groups of patients with Parkinson's disease.
T2	Participants 323 428	10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine.
T3	Participants 462 518	eight patients with L-dopa-induced peak-dose dyskinesia.